HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice
Year: 2013
Type: article
Abstract: Viral diversity is considered a major impediment to the development of an effective HIV-1 vaccine. Despite this diversity, certain protein segments are nearly invariant across the known HIV-1 Group M sequences. We developed immunogens based on the highly conserved elements from the p24(gag) region according to two principles: the immunogen must (i) include strictly conserved elements of the virus that cannot mutate readily, and (ii) exclude both HIV regions capable of mutating without limiting virus viability, and also immunodominant epitopes located in variable regions. We engineered two HIV-1 p24(gag) DNA immunogens that express 7 highly Conserved Elements (CE) of 12-24 amino acids in length and differ by only 1 amino acid in each CE ('toggle site'), together covering >99% of the HIV-1 Group M sequences. Altering intracellular trafficking of the immunogens changed protein localization, stability, and also the nature of elicited immune responses. Immunization of C57BL/6 mice with p55(gag) DNA induced poor, CD4(+) mediated cellular responses, to only 2 of the 7 CE; in contrast, vaccination with p24CE DNA induced cross-clade reactive, robust T cell responses to 4 of the 7 CE. The responses were multifunctional and composed of both CD4(+) and CD8(+) T cells with mature cytotoxic phenotype. These findings provide a method to increase immune response to universally conserved Gag epitopes, using the p24CE immunogen. p24CE DNA vaccination induced humoral immune responses similar in magnitude to those induced by p55(gag), which recognize the virus encoded p24(gag) protein. The inclusion of DNA immunogens composed of conserved elements is a promising vaccine strategy to induce broader immunity by CD4(+) and CD8(+) T cells to additional regions of Gag compared to vaccination with p55(gag) DNA, achieving maximal cross-clade reactive cellular and humoral responses.
Source: PLoS ONE
Authors: Viraj Kulkarni, Margherita Rosati, Antonio Valentin, Brunda Ganneru, Ashish K. Singh, Jian Yan, Morgane Rolland, Candido Alicea, Rachel Kelly Beach, Gen-Mu Zhang, Sylvie Le Gall, Kate E. Broderick, Niranjan Y. Sardesai, David Heckerman, Beatriz Mothe, Christian Brander, David B. Weiner, James I. Mullins, George N. Pavlakis, Barbara K. Felber
Institutions: Frederick National Laboratory for Cancer Research, Center for Cancer Research, University of Pennsylvania, University of Washington, Ragon Institute of MGH, MIT and Harvard, Massachusetts Institute of Technology, Inovio Pharmaceuticals (United States), Microsoft (United States), Universitat Autònoma de Barcelona, IrsiCaixa, Institució Catalana de Recerca i Estudis Avançats
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funders: Bill and Melinda Gates Foundation, Styrelsen för Internationellt Utvecklingssamarbete, Fundación Para La Innovación Y La Prospectiva En Salud En España, National Institutes of Health, Instituto de Salud Carlos III, National Cancer Institute, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W2030852692
